ORKA: ORKA-001 600 mg delivered 61% PASI 100 at Week 16, backing Phase 3 selection

What happened

ORKA-001 600 mg achieved a 61% PASI 100 rate and 86% PASI 90 rate at Week 16 in the EVERLAST-B study, supporting Phase 3 dose selection. Safety was consistent with the IL-23p19 class, and Phase 3 is expected to start in the first half of 2027.

Confirmed

Global impact / market context

PASI 100 means completely clear skin, and 61% is a strong result that supports advancing this drug into larger Phase 3 trials. Success there would move Oruka closer to a marketable therapy, but the 2027 start means revenue is still years away and spending will rise first.

Analyst inference

Oruka is a clinical-stage drug developer, so its value rests on trial results rather than current sales. Strong skin-clearing data can support future fundraising and partnering talks, while the long wait to Phase 3 keeps cash burn and financing risk central for investors.

Analyst inference

What to watch

1. Phase 3 is expected to start in the first half of 2027, so watch for company updates confirming that timeline and any announced trial design details. Confirmed
2. Watch the company's spending on research and its cash available, since a years-long gap before Phase 3 could require raising more money. Analyst inference
3. Watch whether longer follow-up and broader patient groups confirm the 61% complete-clearing rate, because regulators will want consistent safety and efficacy data. Proposed

Evidence

• Original source link unavailable